About This Guide
This guide provides supplementary information for the Hemlibra Dosing Calculator. The tool is designed to assist healthcare professionals in determining the appropriate loading and maintenance doses of emicizumab based on patient weight and the selected dosing regimen. It simplifies the process by recommending an optimal combination of vial strengths to meet the calculated dose while aiming to minimize product waste.
Outputs Explained
After entering the required patient data, the calculator provides the following key outputs for clinical review:
- Required Dose: The precise dose in milligrams (mg) calculated based on the patient's weight in kilograms and the selected dosing rate (e.g., 3 mg/kg).
- Recommended Vial Combination: An optimized list of available vial strengths (e.g., 1 x 150 mg vial + 1 x 60 mg vial) that should be combined to achieve the required dose. The algorithm prioritizes minimizing overage and the total number of vials.
- Total Volume for Injection: The total volume in milliliters (mL) to be administered subcutaneously, based on the sum of the volumes from the recommended vials.
- Administration Note: A critical warning is displayed if the total injection volume exceeds 2 mL, advising that the dose be split into two separate injections.
How to Use the Calculator
Follow these steps to determine the correct dosing and vial combination:
- Enter Patient Weight: Input the patient's weight and select the corresponding unit (kg or lbs). The tool will automatically convert lbs to kg for the calculation.
- Select Dosing Phase: Choose between the "Loading Dose" phase (initial 4 weeks) or the "Maintenance Dose" phase.
- Select Maintenance Regimen: If "Maintenance Dose" is selected, one of the three approved regimens (weekly, every 2 weeks, or every 4 weeks) must be chosen.
- Select Available Vials: Check the boxes corresponding to the Hemlibra vial strengths that are available in your clinic's inventory.
- Calculate and Review: Click the "Calculate" button. The tool will display the detailed dosing recommendation, which must be verified by a qualified healthcare professional before administration.
Dosing Overview
Hemlibra (emicizumab) dosing is administered subcutaneously and consists of two phases as outlined in the prescribing information.
Loading Dose: The induction phase consists of a dose of 3 mg/kg once weekly for the first 4 weeks. This initial period is crucial for achieving therapeutic drug concentrations.
Maintenance Dose: Following the 4-week loading period, dosing transitions to one of three maintenance regimen options, based on clinical judgment and patient preference:
- 1.5 mg/kg once weekly
- 3 mg/kg every 2 weeks
- 6 mg/kg every 4 weeks
Switching from Other Therapies
When transitioning a patient to Hemlibra from bypassing agents or factor VIII replacement therapy, specific clinical guidance is required. The first dose of Hemlibra is typically administered the day after the last dose of the previous treatment. Please consult the full prescribing information for detailed instructions on managing the transition period to minimize the risk of adverse events.
Missed Dose Instructions
Guidance for a missed dose depends on the patient's prescribed maintenance schedule. Patients should be instructed to take the missed dose as soon as they remember and then resume their normal schedule. Two doses should not be administered on the same day. Refer to the official prescribing information for specific instructions based on the weekly, bi-weekly, or quad-weekly regimen.
Safety Alerts
It is critical to review the full Prescribing Information for Hemlibra before use, including the Boxed Warning regarding thrombotic microangiopathy and thromboembolism when used with aPCC.
Frequently Asked Questions
What happens if I enter the weight in lbs?
The calculator automatically converts the weight from pounds (lbs) to kilograms (kg) using a standard conversion factor (1 kg ≈ 2.20462 lbs) before calculating the required dose.
How does the calculator choose the best vial combination?
The algorithm searches for a combination of the selected available vials that meets or slightly exceeds the required dose. It prioritizes the solution that results in the least amount of wasted medication (overage) and, secondarily, uses the fewest number of vials.
Why is the recommended total dose from vials slightly higher than the required dose?
Because doses are supplied in fixed-strength vials, it is often impossible to match the exact weight-based dose. The calculator selects a combination that provides at least the required dose, which may result in a slightly higher total administered dose. This is standard practice and aligns with the product label.
What does the "split into two separate subcutaneous injections" warning mean?
The approved administration guidelines state that a single subcutaneous injection of Hemlibra should not exceed 2 mL in volume. If the total volume of the combined vials is greater than 2 mL, the calculator displays a warning to divide the total volume into two syringes for two separate injections.
Can I use a vial strength that is not selected in the tool?
No, the calculator will only use the vial strengths you have checked as "available." To include other strengths in the calculation, you must select them in the "Select Available Vials" section.
Is this tool a substitute for clinical judgment or official prescribing information?
Absolutely not. This tool is for educational and informational support only. All calculations and recommendations must be independently verified against the official Prescribing Information and confirmed by a qualified healthcare professional.
What is the maximum number of vials the calculator will combine?
The calculator is programmed to find efficient combinations and typically limits its search to combinations of up to five vials to ensure a practical and timely result.
What should I do if the recommended vial combination is not available?
If your inventory changes, you should update the "Select Available Vials" checkboxes and run the calculation again. The tool will find the next best combination based on your updated stock.
References
The information and calculations are based on standard clinical practices and official product labeling. Always consult the most current versions of these resources.
- HEMLIBRA® (emicizumab-kxwh) Prescribing Information. Genentech, Inc.
- Hemlibra Official Healthcare Professional Website. Genentech, Inc.
- Hemlibra European Public Assessment Report (EPAR). European Medicines Agency.
- FDA Approval Information for Hemlibra (emicizumab-kxwh). U.S. Food & Drug Administration.
